Related Experiment Video

Updated: May 21, 2026

Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry
12:31

Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry

Published on: December 8, 2015

Common features at the start of the neurodegeneration cascade

Rubén Hervás1, Javier Oroz, Albert Galera-Prat

  • 1Instituto Cajal, IC-CSIC & Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Plos Biology
|June 6, 2012
PubMed

Insights

Specific protein conformers drive neurodegenerative diseases. A novel method reveals these molecular culprits, offering new targets for diagnosis and treatment of conditions like Alzheimer's and Parkinson's.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Molecular Biology

Background:

  • Amyloidogenic neurodegenerative diseases are incurable and socially impactful.
  • The molecular mechanisms driving these diseases remain poorly understood.
  • A key hypothesis involves conformational changes in monomeric proteins triggering disease.

Purpose of the Study:

  • To investigate the conformational polymorphism of neurotoxic protein monomers.
  • To correlate monomeric conformational states with amyloidogenesis and neurotoxicity.
  • To identify potential therapeutic targets for neurodegenerative diseases.

Main Methods:

  • Utilized force spectroscopy for protein analysis.
  • Employed a novel methodology for single-molecule identification.
  • Analyzed four representative neurotoxic proteins and a fibrillization-incompetent mutant.

Main Results:

  • Demonstrated rich conformational polymorphism in neurotoxic protein monomers.
  • Found a strong correlation between monomeric polymorphism, amyloidogenesis, and neurotoxicity.
  • Observed that familial disease mutations favor this polymorphism, while a specific inhibitor diminishes it.

Conclusions:

  • Specific mechanostable conformers are identified as the cause of amyloidogenic neurodegenerative diseases.
  • These conformers represent novel targets for early diagnosis and therapy.
  • A single pharmacological agent can inhibit conformational heterogeneity, suggesting a common disease pathway.

More Related Videos

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices07:57

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices

Published on: April 11, 2018

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...